ARIAD Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARIAD Pharmaceuticals

ARIA 23.99

0.0%

Feb 17 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Vidpok1	2/3/2016 3:49:50 PM
	of 4474

Another day of following the IBB in lockstep with almost identical charts. No wonder we are at 5, down the same 30 or so percent as the sector. Has been the same for a very long time but in terms of a buyout figure, I think the present value is meaningless. We now have a product in 788 which in the future may yield an enormous amount of revenue for another company. Yes, proof of safety and efficacy remain to be validated but that could happen in a relatively short amount of time, probably in 2017 I would think. By that time 113 will have been approved as well, and the trials to establish ponatinib's eventual role will have created a much clearer picture of that products eventual value. At this point I would think Denner is willing to wait until that time to seek a buyer (not to mention the fact that by 2017 this biotech correction will probably be a long forgotten memory). I think those who look at the current price as a basis to extrapolate a buyout number are missing the larger picture. Denner undoubtedly understands the company's science and potential much better than the retailers who only look at the day to day numbers and dismiss the progress that is ongoing.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next